News

Investor's Business Daily on MSN5h
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key." ...